Humacyte, Inc

HUMANASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

277.8M

on 2026-06-30, from 119.1M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$350.0M

S-3 of 2025-09-12. 4 prospectus supplements filed under it since. S-3 ↗

$60.0M

TD Securities (USA), agreement of 2025-12-16. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

42.78M

Warrants of every class as tagged in the XBRL facts on 2026-06-30. 10-Q ↗

Cash

3.3 quarters

$79.9M on 2026-06-30 ÷ $24.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-06-10	Public offering	47,619,048	$1.05	$50.0M	424B5 ↗
2026-03-19	Public offering	25,000,000	$0.80	$20.0M	424B3 ↗
2025-12-15	Public offering	5,725,190	not read	not read	424B3 ↗
2025-10-06	Public offering	28,436,018	$2.11	$60.0M	424B3 ↗
2025-10-06	Registered direct offering	28,436,018	not read	not read	8-K ↗
2025-03-25	Public offering	25,000,000	$2.00	$50.0M	424B5 ↗

Also on file: up to $40.0M term loan agreed 2025-12-15 8-K ↗